This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.

3veh

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Current revision

Structure of a M. tuberculosis salicylate synthase, MbtI, in complex with an inhibitor methylAMT

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3veh"

@@ Line 3: / Line 3: @@
 <StructureSection load='3veh' size='340' side='right'caption='[[3veh]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[3veh]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/"bacillus_tuberculosis"_(zopf_1883)_klein_1884 "bacillus tuberculosis" (zopf 1883) klein 1884]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VEH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3VEH FirstGlance]. <br>
+<table><tr><td colspan='2'>[[3veh]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VEH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3VEH FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=0GA:3-{[(1Z)-1-CARBOXYPROP-1-EN-1-YL]OXY}-2-HYDROXYBENZOIC+ACID'>0GA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=SCN:THIOCYANATE+ION'>SCN</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3rv6|3rv6]], [[3rv7|3rv7]], [[3rv8|3rv8]], [[3rv9|3rv9]], [[3st6|3st6]]</div></td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=0GA:3-{[(1Z)-1-CARBOXYPROP-1-EN-1-YL]OXY}-2-HYDROXYBENZOIC+ACID'>0GA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=SCN:THIOCYANATE+ION'>SCN</scene></td></tr>
-<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">mbtI, trpE2, Rv2386c, MT2454 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1773 "Bacillus tuberculosis" (Zopf 1883) Klein 1884])</td></tr>
 <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3veh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3veh OCA], [https://pdbe.org/3veh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3veh RCSB], [https://www.ebi.ac.uk/pdbsum/3veh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3veh ProSAT]</span></td></tr>
 </table>
 == Function ==
-[[https://www.uniprot.org/uniprot/MBTI_MYCTU MBTI_MYCTU]] Mediates the production of salicylate from chorismate via an isochorismate intermediate. Presents both isochorismate synthase and isochorismate-pyruvate lyase activities. Salycilate is the starter unit in the production of the virulence-conferring salicylate-based siderophore mycobactin.<ref>PMID:16923875</ref>
+[https://www.uniprot.org/uniprot/MBTI_MYCTU MBTI_MYCTU] Mediates the production of salicylate from chorismate via an isochorismate intermediate. Presents both isochorismate synthase and isochorismate-pyruvate lyase activities. Salycilate is the starter unit in the production of the virulence-conferring salicylate-based siderophore mycobactin.<ref>PMID:16923875</ref>
-<div style="background-color:#fffaf0;">
-== Publication Abstract from PubMed ==
-MbtI is the salicylate synthase that catalyzes the first committed step in the synthesis of the iron chelating compound mycobactin in Mycobacterium tuberculosis. We previously developed a series of aromatic inhibitors against MbtI based on the reaction intermediate for this enzyme, isochorismate. The most potent of these inhibitors had hydrophobic substituents, ranging in size from a methyl to a phenyl group, appended to the terminal alkene of the enolpyruvyl group. These compounds exhibited low micromolar inhibition constants against MbtI and were at least an order of magnitude more potent than the parental compound for the series, which carries a native enolpyruvyl group. In this study, we sought to understand how the substituted enolpyruvyl group confers greater potency, by determining cocrystal structures of MbtI with six inhibitors from the series. A switch in binding mode at the MbtI active site is observed for inhibitors carrying a substituted enolpyruvyl group, relative to the parental compound. Computational studies suggest that the change in binding mode, and higher potency, is due to the effect of the substituents on the conformational landscape of the core inhibitor structure. The crystal structures and fluorescence-based thermal shift assays indicate that substituents larger than a methyl group are accommodated in the MbtI active site through significant but localized flexibility in the peptide backbone. These findings have implications for the design of improved inhibitors of MbtI, as well as other chorismate-utilizing enzymes from this family.
-Implications of Binding Mode and Active Site Flexibility for Inhibitor Potency against the Salicylate Synthase from Mycobacterium tuberculosis.,Chi G, Manos-Turvey A, O'Connor PD, Johnston JM, Evans GL, Baker EN, Payne RJ, Lott JS, Bulloch EM Biochemistry. 2012 Jun 7. PMID:22607697<ref>PMID:22607697</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 3veh" style="background-color:#fffaf0;"></div>
 ==See Also==
@@ Line 28: / Line 18: @@
 </StructureSection>
 [[Category: Large Structures]]
-[[Category: Baker, E N]]
+[[Category: Mycobacterium tuberculosis]]
-[[Category: Bulloch, E M]]
+[[Category: Baker EN]]
-[[Category: Chi, G]]
+[[Category: Bulloch EM]]
-[[Category: Johnston, J M]]
+[[Category: Chi G]]
-[[Category: Lott, J S]]
+[[Category: Johnston JM]]
-[[Category: Manos-Turvey, A]]
+[[Category: Lott JS]]
-[[Category: Payne, R J]]
+[[Category: Manos-Turvey A]]
-[[Category: Structural genomic]]
+[[Category: Payne RJ]]
-[[Category: Isomerase]]
-[[Category: Lyase]]
-[[Category: Salicylate synthase]]
-[[Category: Tbsgc]]

3veh

From Proteopedia

Current revision

Structure of a M. tuberculosis salicylate synthase, MbtI, in complex with an inhibitor methylAMT

Structural highlights

Function

See Also

References

Contents

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox